Potent autotaxin inhibitor (IC50
= 2.8 nM in isolated enzyme assay; 101 nM in human whole blood). Modulates lysophosphatidic acid (LPA) levels in vivo
and in vitro
by directly inhibiting autotaxin; reduces LPA levels both in plasma and at site of inflammation. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse et al.
Autotaxin: its role in biology of melanoma cells and as a pharmacological target.
Enzyme Res., 2011;:194857